Nasdaq:US$18.12 (-0.52) | HKEX:HK$28.75 (-0.90) | AIM:£2.93 (-0.03)
News & Presentations
Previous Article   |   Next Article
Announcements & Press Releases, Regulatory Notice | 14 Apr 2021

Notification of Dilution of Voting Rights

Hong Kong, Shanghai, & Florham Park, NJ: Wednesday, April 14, 2021:  Hutchison China MediTech Limited (“HUTCHMED”) (Nasdaq/AIM: HCM) was notified that CK Hutchison Holdings Limited (“CK Hutchison”) shareholding[1] in HUTCHMED remains unchanged, at 332,478,770 ordinary shares of par value US$0.10 each in the capital of HUTCHMED (“Shares”).

Each American Depositary Share (“ADS”) represents five Shares.  As announced on April 8, 2021, HUTCHMED issued a total of 16,393,445 Shares (equivalent to 3,278,689 ADSs) to funds affiliated with Baring Private Equity Asia.  HUTCHMED was notified on April 14, 2021 that this issuance diluted CK Hutchison’s holding[1] to 44.66 per cent of the total number of voting rights of HUTCHMED.  The date on which the notification threshold was crossed was April 14, 2021.

[1] Held through CK Hutchison’s indirect wholly-owned subsidiary Hutchison Healthcare Holdings Limited.



HUTCHMED (Nasdaq/AIM: HCM) is an innovative, commercial-stage, biopharmaceutical company.  It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. A dedicated organization of over 1,200 personnel has advanced ten cancer drug candidates from in-house discovery into clinical studies around the world, with its first two oncology drugs now approved and launched. For more information, please visit: or follow us on LinkedIn.



Investor Enquiries

Mark Lee,
Senior Vice President
+852 2121 8200
Annie Cheng,
Vice President
+1 (973) 567 3786

Media Enquiries

Brad Miles,
Solebury Trout
+1 (917) 570 7340 (Mobile)
Ben Atwell / Alex Shaw,
FTI Consulting
+44 20 3727 1030 /
+44 7771 913 902 (Mobile) /
+44 7779 545 055 (Mobile)
Joseph Chi Lo,
+852 9850 5033 (Mobile)
Zhou Yi,
+852 9783 6894 (Mobile)

Nominated Advisor

Freddy Crossley /
Atholl Tweedie,
Panmure Gordon (UK) Limited
+44 (20) 7886 2500